Background {#Sec1}
==========

*BRCA*1 and *BRCA*2 *(BRCA*1/2 hereafter) are tumor suppressor genes involved in DNA repair and maintenance of genomic stability. Mutations in *BRCA*1/2 genes account for 20 to 25% of all hereditary breast cancers \[[@CR1]\] and about 5--10% of all breast cancers \[[@CR2]\]. Pathogenic *BRCA*1/2 mutations are highly penetrant mutations that are inherited in an autosomal dominant fashion and result in a significantly increased risk of breast, ovarian, prostate, melanoma, pancreatic and other cancers \[[@CR3]--[@CR7]\]. While there has been extensive research on the risk of cancer in women with *BRCA*1/2 mutations, the cancer characteristics of men with *BRCA*1/2 mutations have not been well studied.

Men with *BRCA*1/2 mutations are at increased risk for breast, prostate, pancreatic and other cancers \[[@CR3]--[@CR5], [@CR8]\]. Male breast cancer is rare in the general population with a lifetime risk of 0.1%, although the risk is significantly increased to 7-8% with *BRCA*2 mutation and 1% with a *BRCA*1 mutation \[[@CR3], [@CR4]\]. Up to 14% of men diagnosed with breast cancer are found to harbor a *BRCA*2 mutation \[[@CR8]\]. Two prior studies have reported worse prognosis in male breast cancer patients with a deleterious *BRCA*1/2 mutation compared to those without a mutation \[[@CR9], [@CR10]\]. However, both studies were limited by their small sample size. There is limited knowledge about the clinical characteristics of male *BRCA*1/2 mutation carriers.

The risk of prostate cancer is up to fivefold higher in *BRCA*2 mutation carriers \[[@CR5], [@CR6]\]. *BRCA*1/2 mutation associated prostate cancers have been reported to be more aggressive and associated with a worse survival compared to *BRCA* wild type cancers \[[@CR11]--[@CR14]\]. Castro et al. reported on 79 patients with prostate cancer who were positive for a *BRCA*1/2 mutation and found that these patients frequently presented with higher Gleason scores (≥ 8), higher T stage (T3 or T4), nodal involvement and metastases at diagnosis \[[@CR12]\].

*BRCA*1/2 associated breast cancers have been known to respond better to platinum based chemotherapy \[[@CR15]\]. Knowledge of *BRCA*1/2 mutation status can have therapeutic implications which can impact survival. PARP (poly adenosine diphosphate-ribose polymerase) inhibitors are being used increasingly in advanced breast and ovarian cancer in women \[[@CR16]--[@CR19]\]. These findings are expanding to treatment of male *BRCA* associated cancers. A recent study demonstrated a significant response to a PARP inhibitor, Olaparib, in patients with advanced castrate resistant prostate cancer with *BRCA* mutations \[[@CR20]\]. Whether these therapeutic agents and the knowledge of *BRCA* mutation status translate to better outcomes in men is not yet known.

In summary, while little is known about the clinical characteristics and outcomes of male *BRCA* mutation carriers, there is a growing imperative to expand our understanding of this unique population. We present an analysis of male *BRCA* mutation carriers from our cancer genetics clinic database and describe their unique features and outcomes.

Methods {#Sec2}
=======

After Institutional Review Board approval, we performed a retrospective chart review on male *BRCA*1/2 mutation carriers identified at the Nancy and James Grosfeld Cancer Genetics Center from January 2004 to December 2014. Patients with a pathogenic or likely pathogenic *BRCA*1/2 mutation were included in the study, while those with variants of undetermined significance were excluded. We used CLIA certified commercial laboratories such as Ambry, Myriad and Invitae, (which are widely used in academic centers), to obtain the information about pathogenicity, which was also individually verified for concordance using databases such as ClinVar. We looked at the demographic information including their age, race, ethnicity and reason for testing. We then studied the subset of male *BRCA*1/2 mutation carriers who were diagnosed with cancer, either prior to or after the testing was performed. We evaluated the type of cancer, clinical staging, histo-pathologic information, treatment and survival. We used SPSS version- 21 statistical software for data analysis.

Results {#Sec3}
=======

Demographics {#Sec4}
------------

A total of 102 male patients were identified who tested positive for a *BRCA*1/2 deleterious mutation. Fifty-three (52%) of these 102 patients were positive for a *BRCA*1 mutation and 49 (48%) were positive for a *BRCA*2 mutation. The median age at the time of testing was 55 years (Range: 19-85 years).

The race and ethnicities of these 102 individuals are included in Table [1](#Tab1){ref-type="table"}. The majority were Caucasian, of whom a quarter were Ashkenazi Jewish.Table 1Ethnicities of male *BRCA* mutation carriersRace/ethnicityTotal *BRCA* mutation carriers (%)Diagnosed with cancer (%)Caucasian97 (95)32 (97) Ashkenazi Jewish25 (25)10 (30) Iraqi3 (3)3 (9) Greek1 (1)1 (3) Lebanese1 (1)1 (3) Hispanic1 (1)1 (3)African American2 (2)1 (3)Asian3 (3)-- Indian1 (1)-- Filipino2 (2)--Total10233

Genetic testing {#Sec5}
---------------

The most common reasons for testing were a family history of breast or ovarian cancer or a known *BRCA*1/2 mutation in the family, which was present in 98 of the 102 patients. A new diagnosis of male breast cancer prompted *BRCA*1/2 testing in the 4 individuals without a family history of breast and ovarian cancer.

Of the non-Ashkenazi Jewish population, 66 patients (86%) underwent single site testing, 9 patients (12%) had full sequence testing and 2 (2%) had multi-gene panel testing. Of the 25 Ashkenazi Jewish patients who tested positive for a *BRCA*1/2 mutation, the majority were identified using the 3 site Ashkenazi Jewish panel, while an additional 3 patients were identified to carry an elsewhere mutation, after being tested negative for the 3 site Ashkenazi Jewish panel.

Cancer characteristics {#Sec6}
----------------------

Of the 102 patients who tested positive for a *BRCA*1/2 mutation, 33 (32%) had a diagnosis of cancer (Fig. [1](#Fig1){ref-type="fig"}). Of these 33 patients with cancer, the majority (20 patients) were found to carry a *BRCA2* mutation. Median age of diagnosis with cancer was 65 years (Range: 35-75 years). A total of 44 cancers were diagnosed in these 33 patients.Fig. 1*BRCA* mutation carriers and diagnosis of cancer

Of the 33 patients diagnosed with cancer, the majority (25 patients) had 1 cancer. A quarter of patients (8 patients) had more than 1 cancer. Of these 8 patients, 6 had 2 cancers, 1 patient had 3 cancers (breast, prostate and lymphoma) and 1 patient had 4 different cancers (breast cancer, DCIS, prostate and small cell neuroendocrine cancer) (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Of the 8 patients diagnosed with multiple cancers, the majority (7 patients) had a *BRCA*2 mutation. A third (7 patients) of the 20 *BRCA*2 mutated patients with cancer had multiple cancers.Fig. 2Types of cancers diagnosed in 33 male *BRCA* mutation carriers

Prostate cancer was the most commonly diagnosed cancer, followed by male breast cancer, bladder cancer, melanoma and other skin cancers (Fig. [1](#Fig1){ref-type="fig"}, Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Ten patients had a diagnosis of non-melanoma skin cancer. Other cancers diagnosed in this group included pancreatic cancer, small cell neuroendocrine cancer, squamous cell lung cancer and lymphomas (Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).Table 2Cancer characteristics of male *BRCA* mutation carriers with prostate cancerPatient IDBRCA GeneMutationAge at diagnosisPSAStageTNMGleasonSurgeryRTADTStatusF/U\
(Yrs)151c.181 T \> G51N.AIIT2Nx7yesN.AN.AAlive, NED5.4101c.4096 + 1 G \> A80N.ANAN.AN.ANAyesN.AAlive, NED1342c.100 G \> T72N.ANAN.A6Yes, RPNANAAlive, NED10.132c.1813dupA587.9IT1 N06NAyesN.AAlive, NED15.652c.2808del466N.AN.AN.AN.AN.AyesN.AAlive, NED512c.2808del467N.AearlyN.A6noyes, EBRTLeuprolide-3 yearsAlive, NED7.1122c.5576del47520.84IVN.A9noPalliative RT to spineLeuprolideExpired0.3162c.5576del470N.AIIIT3 N08yes, RPN.ALeuprolideAlive, NED10142c.5946delT642.7N.AN.AN.Ayes, RPN.AN.AN.AN.A72c.5946delT74N.AN.AN.A7yes, RPN.ALeuprolideAlive, NED8.1132c.7558 C \> T67N.AIIT2,N07nobrachytherapyN.AAlive, NED7.6112c.9317G \> A65N.AIIT2 N07Yes,RPN.AN.AAlive, NED5.262c.6333_6337delGAGAA681497IVN.AN.AN.AN.ABicalutamide, Leuprolide, AbirateroneExpired2.2*RT* radiation therapy, *RP* Radical prostatectomy, *ADT* androgen deprivation therapy, *NED* no evidence of disease, *NA* not available, *PSA* value in ng/ml, cutoff value 4 ng/mlTable 3Cancer characteristics of male *BRCA* mutation carriers with breast cancerIDBRCA GeneMutationAge at diagnosisSize (cm)LNStageTNM stageGradeER\
%PR\
%HER-2SurgeryChemoRTStatusF/U (yrs)4*2*c.100G \> T751.4negIT1N0M029218posMYes, TrastuzumabnoAlive, NED5.78*2*c.736del2052N.AN.AN.AN.A39787Border-lineMyes, TCHyesAlive5.63*2*c.1813dupA581.3posIIT2N1M035950negMyes, ACyesExpired15.85*2*c.2808del4671.7posIIIT1N3M0310089posMyes, ACTHyesAlive, NED3.41*2*c.2808del4681.6posIIT2N1M039040negMYes, AC-TyesAlive, NED7.07*2*c.5946del T62N.AposIIN.A390N.AN.AMYes,CMFyesAlive, NED21.09*2*c.5946delT67N.AN.AN.AN.AN.AN.AN.AN.AN.AN.AN.AN.AN.A2*2*c.6676_6677delGA622.5posIIT2N1M0210037posMyes, TCHPnoAlive, NED1.86*2*c.6333_6337delGAGAA686.0posIIIT4N2M039729negMN.AN.AExpired2.3*LN* lymph node status, *RT* radiation therapy, *M* mastectomy, *AC-T* Doxorubicin, Cyclophosphamide and Paclitaxel, *TCHP* Docetaxel, Carboplatin, Trastuzumab and Pertuzumab, *AC* Doxorubicin and Cyclophosphamide, *ACTH* Doxorubicin, Cyclophosphamide, Paclitaxel and Trastuzumab, *CMF* Cyclophosphamide, Methotrexate and Fluorouracil, *TCH* Docetaxel, Carboplatin and Trastuzumab, *NED* no evidence of disease, *F/U* follow-up, *NA* not available, *neg* negative, *pos* positiveTable 4Other cancers diagnosed in male *BRCA* mutation carriersCancerPatient IDBRCA gene*Mutation*Age at dxStageSurgeryChemotherapyRTStatusF/U (Yrs)Melanoma\
*N* = 3191c.66dupA36EarlyyesnonoN.AN.A171c.68delAG62IVN.AYes (Cisplatin, PARP inhibitor clinical trial)yesexpired0.9181del exons 1-767earlyyesnonoN.AN.ABladder\
N = 3202c.5576del447earlyYes (TURBT)nonoN.AN.A222c.5782 G \> T70IVYes (nephro-ureterectomy)Yes (Carboplatin, Paclitaxel, Pemetrexedyesexpired2.4212c.5946delT59earlyYes (TURBT)nonoAlive, NED4.7Squamous cell lung cancer231c.5123C \> A87IIINo (declined)No (declined)No (declined)expired1.1Neuroendocrine carcinoma32c.1813dupA73IVnoYes (Carboplatin, Etoposide)noexpired1.4Pancreas241c.2475delC60IVN.AYes (Gemcitabine, Carboplatin, FOLFOX)noExpired4.2Lymphoma12c.2808del468N.AN.AN.AN.AN.AN.ACLL251c.68delAG50N.AN.AN.AN.Aalive1.1Other Cancers *N* = 10281c.68delAG65earlyyesN.AN.AaliveN.A261c.2475delC55earlyyesN.AN.AN.AN.A301c.4524G \> A55earlyyesN.AN.AN.AN.A231c.5123C \> A74earlyyesN.AN.AN.AN.A291c.5266dupC37earlyyesN.AN,AN.AN.A311del exons 13-15NAearlyyesN.AN.AN.AN.A222c.5782G \> T58earlyyesN.AN.AN.AN.A332c.9196C \> T60earlyyesN.AN.AN.AN.A272c.9382C \> T35earlyyesN.AN.AN.AN.A3221881 delC70earlyyesN.AN.AN.AN.A*RT* radiation therapy, *F/U* follow-up, *TURBT* transurethral resection of bladder tumor, *FOLFOX* Infusional fluorouracil, leukovorin and oxaliplatin, *N.A* not available

### Prostate cancer {#Sec7}

Thirteen patients had a diagnosis of prostate cancer (Table [2](#Tab2){ref-type="table"}). The majority (11) of these patients had a *BRCA*2 mutation. Median age at diagnosis with prostate cancer was 68 years (Range: 51 to 80 years). Of the 4 patients for whom PSA (prostate specific antigen) data was available, the median PSA level at diagnosis was 14.37 ng/ml (Range: 2.7 to 1497 ng/ml). Of the 8 patients for whom staging information was available, 3 had stage II disease, 2 patients had stage I disease, 2 had stage IV disease and 1 patient had stage III disease. Of the 9 patients for whom Gleason score was available, the median Gleason score was 7 (Range: 6-9). Most patients were treated with either radical prostatectomy (6 patients) or primary radiation therapy (5 patients). The remaining 2 patients had stage IV disease and were treated with palliative chemotherapy (Docetaxel), androgen deprivation therapy (ADT) and palliative radiation therapy to the spine.

Survival data was available for 12 patients. Two patients died during a median follow-up of 7.4 years (Range: 0.3 - 15.6 years). One patient died 4 months after diagnosis from stage IV disease with extensive bone, liver and lung metastases and another patient died at 2.2 years, also from extensive bone and liver metastases. The 1- and 5-year survival was 91.6% and 83.3% respectively (Fig. [3](#Fig3){ref-type="fig"}). The 5- year prostate cancer specific survival was 83.3%.Fig. 3Kaplan-Meier curve showing overall survival in male *BRCA* mutation carriers with prostate cancer

### Male breast cancer {#Sec8}

Nine patients had a diagnosis of male breast cancer (Table [3](#Tab3){ref-type="table"}). All of these 9 patients had a *BRCA*2 mutation. Median age at breast cancer diagnosis was 67 years (Range: 52-75 years). All of the 8 patients for whom pathology was available, had infiltrating ductal carcinomas and one of these also had a contralateral DCIS (ductal carcinoma in situ). All of these 8 patients had hormone receptor ER (estrogen receptor) positive cancers and 6 had high grade histology. Of the 7 patients for whom lymph node status was available, 6 patients had lymph node metastases at diagnosis. Staging information was available for 7 patients. Four of these 7 patients had stage II disease, 1 patient had stage I disease and 2 patients had stage III disease. Four out of the 7 patients for whom human epidermal growth factor receptor (HER-2) status was available, were HER − 2 positive. Eight patients had available surgical treatment data and all eight patients underwent a mastectomy. Five of the 9 breast cancer patients received adjuvant radiation therapy. Seven patients received chemotherapy, as depicted in Table [3](#Tab3){ref-type="table"}. All but 1 patient took Tamoxifen. Two patients died during a median follow-up of 5.6 years. One patient died 15.8 years after diagnosis, from small cell neuroendocrine cancer and another patient died 2.3 years after diagnosis from widely metastatic prostate cancer. There were no breast cancer associated deaths. The 1- and 5- year survival was 100% and 83.3% respectively (Fig. [4](#Fig4){ref-type="fig"}). The 5- year breast cancer specific survival was 100%.Fig. 4Kaplan-Meier curve showing overall survival in male *BRCA* mutation carriers with breast cancer

### Other cancers {#Sec9}

Three patients were diagnosed with malignant melanoma. Ten patients were diagnosed with non-melanoma skin cancers (Table [4](#Tab4){ref-type="table"}). One of the 3 patients with melanoma had an aggressive anal melanoma, which presented with stage IV disease. This patient was treated with multiple lines of chemotherapy including Cisplatin as well as a PARP inhibitor. He initially had a good response to the PARP inhibitor, but eventually succumbed to the disease. Three patients were diagnosed with bladder carcinoma. One patient was diagnosed with metastatic pancreatico-biliary adenocarcinoma. One patient had small cell neuroendocrine carcinoma of liver and was treated with Carboplatin and Etoposide chemotherapy. One patient was diagnosed with squamous cell lung carcinoma and elected for hospice care in view of advanced age and multiple co-morbidities.

Discussion {#Sec10}
==========

This study represents one of the largest retrospective studies of cancers in male *BRCA*1/2 mutation carriers, consisting of 102 male patients who were identified in a clinical cohort. Given the paucity of recent literature on cancer characteristics in male *BRCA* mutation carriers, this study will help enhance our understanding of the cancer characteristics in this unique population. The most common reason for testing among our male population was a family history of breast and ovarian cancer, which was present in 98 (96%) of the 102 patients. Only 4 of the 102 patients were tested after their own cancer diagnosis. It is important to be aware that male breast cancer may be the first manifestation of a *BRCA* mutation in a family, reinforcing the NCCN recommendation that every male breast cancer patient should be tested for a *BRCA* mutation \[[@CR21]\].

Despite having a family history of breast and ovarian cancer, the majority of males in our study underwent single site testing, suggesting that testing typically occurred after another family member was identified with a mutation. Other studies have also shown that males are less likely to test for *BRCA* mutations \[[@CR22]--[@CR24]\]. Despite autosomal inheritance, males tend to be less likely to be the first in the family to test. One possible reason for this observation is physician bias regarding *BRCA* impacting women given the well-known association of *BRCA* mutation with female cancers. Other reasons include lack of awareness that breast cancer can affect men or that breast cancer genes can be transmitted by males and also less willingness of males with regard to genetic testing \[[@CR22]--[@CR24]\].

Almost a third of male patients with a *BRCA* mutation had a diagnosis of cancer, but only 4 patients were tested because of the cancer diagnosis. The median age of diagnosis of any cancer was 65 years. There was no identifiable pattern of mutations with respect to the region of the gene or the type of mutation, among the people unaffected by cancer, compared to those who developed a cancer. Of the 20 *BRCA*2 mutation carriers with cancer, over a third (7 patients) had multiple cancers. Physicians need to be vigilant to the possibility of synchronous or metachronous development of new cancers in the *BRCA* mutation carriers, especially those with a *BRCA*2 mutation. Prostate cancer was the most common cancer diagnosed in this population followed by male breast cancer, skin cancer, bladder cancer and others.

The majority of cancers were seen in *BRCA*2 mutation carriers, which is consistent with previously reported data \[[@CR3]--[@CR7]\]. The majority of *BRCA* associated male breast cancers were high grade, hormone receptor positive and associated with lymph node metastases, which is also consistent with previously reported data \[[@CR25]\] It is interesting to note that all of the 7 patients for whom chemotherapy data was available, received chemotherapy. There were no breast cancer related deaths. The impact of chemotherapy on the excellent survival noted in this cohort of patients is intriguing. Homologous recombination repair deficiency seen in *BRCA* mutated cancers confers higher sensitivity to chemotherapy, especially to DNA damaging agents such as platinum based therapies, due to impaired ability to repair double strand breaks. More than two thirds of patients with breast cancer were alive with no evidence of disease, at a median follow-up of 5.6 years.

Although limited by small size, our study shows that *BRCA* mutation carriers with prostate cancer had higher Gleason scores, elevated PSA levels and more advanced stage disease, consistent with prior reports \[[@CR12]--[@CR14]\]. The median age of diagnosis with prostate cancer was 68 years, lending support to the recent change in NCCN guidelines to increase the age of prostate cancer screening in *BRCA* mutation carriers from 40 to 45 years \[[@CR21]\].

Of the less common cancers, we observed 1 pancreatic cancer that was interestingly identified in a *BRCA*1 mutation carrier. The risk of uveal melanoma (a rare type of melanoma) has been reported to be higher in *BRCA*2 mutation carriers \[[@CR7]\]. We had 3 patients who were diagnosed with melanoma in our study, but neither one of them had an uveal melanoma. One patient had an aggressive stage IV anal melanoma and demonstrated an excellent initial response to a PARP inhibitor on a clinical trial. This observation supports further research into PARP inhibitors in other *BRCA* related cancers.

Our study had a few limitations, including being a single institution retrospective analysis as well as limited access to treatment records, and somewhat short follow-up.

Conclusions {#Sec11}
===========

This study represents one of the largest studies describing the cancer characteristics of male *BRCA* mutation carriers. We demonstrated that the majority of cancers seen were breast and prostate with high grade histology and more advanced stages. Favorable impact of systemic chemotherapy may explain the excellent survival in the male breast cancer group. Additional studies are needed with large numbers of patients to better understand the cancer characteristics of male *BRCA* mutation carriers.

AC

:   Doxorubicin and cyclophosphamide

AC-T

:   Doxorubicin, cyclophosphamide and paclitaxel

ACTH

:   Doxorubicin, cyclophosphamide, paclitaxel and trastuzumab

ADT

:   Androgen deprivation therapy

CMF

:   Cyclophosphamide, methotrexate and fluorouracil

DCIS

:   Ductal carcinoma in situ

ER

:   Estrogen receptor

F/U

:   Follow-up

FOLFOX

:   Infusional fluorouracil, leucovorin and oxaliplatin

HER-2

:   Human epidermal growth factor receptor-2

LN

:   Lymph node

M

:   Mastectomy

NED

:   No evidence of disease

PARP

:   Poly adenosine diphosphate-ribose polymerase

PSA

:   Prostate specific antigen

RT

:   Radiation therapy

TCH

:   Docetaxel, carboplatin and trastuzumab

TCHP

:   Docetaxel, carboplatin, trastuzumab and pertuzumab

TURBT

:   Transurethral resection of bladder tumor
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